Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Pharm Pharm Sci ; 7(1): 8-12, 2004 Jan 23.
Artigo em Inglês | MEDLINE | ID: mdl-15144729

RESUMO

PURPOSE: Effect of caprylocaproyl macrogolglycerides (Labrasol), as a lipoidic excipient/vehicle in an oral capsule formulation, on pharmacokinetic disposition of a BCS Class 3 compound, UK-81252, was investigated in vivo in a canine model. METHODS: The control and lipoidic formulations were administrated to six Beagle dogs in a crossover, single dose design with a 2-week washout period in between treatments. The plasma concentration-time profile for the lipoidic formulation was compared to that of the control formulation (lactose-based oral capsule). RESULTS: Although the lipoidic formulation resulted in a markedly increased oral bioavailability (based on mean pharmacokinetic parameters, AUC(0-48 hr) and C(max) ), a double-peaking phenomenon was observed with this formulation. The most likely cause of this double-peak effect was the gastric emptying retardation attribute of the lipoidic vehicle/excipient. The initial peak (Tmax1) was due to the absorption enhancing properties of the lipoidic formulation and the second peak (Tmax2) was most likely the result of a shutdown in gastric emptying for a period of up to 2 hours (this value varied between dogs) after which the remaining Compound UK 81252 emptied from the stomach to generate the second peak. CONCLUSIONS: Caprylocaproyl macrogolglycerides enhanced the absorption of Compound UK 81252. After oral administration, the liquid-filled formulation consistently produced a double-peak phenomenon in the plasma profile. Labrasol was determined to be the most likely culprit for this double peaking phenomenon.


Assuntos
Absorção/efeitos dos fármacos , Emulsões/farmacologia , Excipientes/farmacologia , Mesilatos/farmacocinética , Tirosina/análogos & derivados , Tirosina/farmacocinética , Administração Oral , Animais , Área Sob a Curva , Disponibilidade Biológica , Cães , Interações Medicamentosas , Glicerídeos , Mesilatos/sangue , Mesilatos/química , Compostos Orgânicos , Tirosina/sangue , Tirosina/química
2.
Drug Dev Ind Pharm ; 30(3): 297-302, 2004 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-15109029

RESUMO

Combined effects of cosolvency and inclusion complexation on drug solubility were studied using a model hydrophobic compound (carbamazepine) and a model hydrophilic compound (Compound S). Propylene glycol (PG) was used as the nonaqueous solvent, and deionized water was employed for the aqueous systems. Hydroxypropyl beta-cyclodextrin (HPbetaCD) was chosen as the complexing agent and studied at concentrations up to 28% (w/v). Complex formation constants (Kc) and solubility enhancement ratios were determined for the respective compounds in various water/PG vehicles. The data suggested that the inclusion of the compounds was most favorable when water alone was used as the vehicle. However, the combined approach of cosolvency and complexation resulted in a significant increase in the total apparent solubility of carbamazepine (the hydrophobic compound). The same was not observed with Compound S (the hydrophilic model), since PG weakened the interactions between the molecule and HPbetaCD, and thus, no synergistic or additive effects were observed with the combined approach of complexation and cosolvency.


Assuntos
Carbamazepina/química , Ciclodextrinas/química , Excipientes/química , Propilenoglicol/química , Água/química , beta-Ciclodextrinas , 2-Hidroxipropil-beta-Ciclodextrina , Cromatografia Líquida de Alta Pressão , Cromatografia Líquida , Composição de Medicamentos , Espectrometria de Massas , Solubilidade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...